1. Home
  2. AIM vs MNDR Comparison

AIM vs MNDR Comparison

Compare AIM & MNDR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AIM
  • MNDR
  • Stock Information
  • Founded
  • AIM 1966
  • MNDR 2016
  • Country
  • AIM United States
  • MNDR Singapore
  • Employees
  • AIM N/A
  • MNDR N/A
  • Industry
  • AIM Biotechnology: Biological Products (No Diagnostic Substances)
  • MNDR
  • Sector
  • AIM Health Care
  • MNDR
  • Exchange
  • AIM Nasdaq
  • MNDR Nasdaq
  • Market Cap
  • AIM 8.8M
  • MNDR 9.3M
  • IPO Year
  • AIM N/A
  • MNDR 2024
  • Fundamental
  • Price
  • AIM $0.12
  • MNDR $1.80
  • Analyst Decision
  • AIM Strong Buy
  • MNDR
  • Analyst Count
  • AIM 2
  • MNDR 0
  • Target Price
  • AIM $2.75
  • MNDR N/A
  • AVG Volume (30 Days)
  • AIM 476.8K
  • MNDR 80.5K
  • Earning Date
  • AIM 03-27-2025
  • MNDR 05-16-2025
  • Dividend Yield
  • AIM N/A
  • MNDR N/A
  • EPS Growth
  • AIM N/A
  • MNDR N/A
  • EPS
  • AIM N/A
  • MNDR N/A
  • Revenue
  • AIM $170,000.00
  • MNDR $13,968,535.00
  • Revenue This Year
  • AIM N/A
  • MNDR $188,831.77
  • Revenue Next Year
  • AIM $1,693.10
  • MNDR $76.44
  • P/E Ratio
  • AIM N/A
  • MNDR N/A
  • Revenue Growth
  • AIM N/A
  • MNDR 77.38
  • 52 Week Low
  • AIM $0.11
  • MNDR $0.23
  • 52 Week High
  • AIM $0.62
  • MNDR $29.50
  • Technical
  • Relative Strength Index (RSI)
  • AIM 42.13
  • MNDR N/A
  • Support Level
  • AIM $0.11
  • MNDR N/A
  • Resistance Level
  • AIM $0.16
  • MNDR N/A
  • Average True Range (ATR)
  • AIM 0.01
  • MNDR 0.00
  • MACD
  • AIM 0.00
  • MNDR 0.00
  • Stochastic Oscillator
  • AIM 5.00
  • MNDR 0.00

About AIM AIM ImmunoTech Inc.

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

About MNDR Mobile-health Network Solutions Class A Ordinary Shares

Mobile-health Network Solutions is a company engaged in providing telehealth solutions in terms of various matrices, such as the number of patient consultations per day and the ranking of its mobile application. It provides services on its MaNaDr platform, which is accessible via mobile application and website. The MaNaDr platform is a platform designed and created by doctors, for doctors and users, equipped with services like consultations with doctors, e-commerce pharma store, and others. The company's operating segments are Telemedicine and other services which is also its key revenue generating segment, and Sale of medicine and medical devices. Geographically, it derives revenue from Singapore.

Share on Social Networks: